The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC).

Dejan  Juric

Stock and Other Ownership Interests  - PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics

Consulting or Advisory Role - AstraZeneca; Eisai; Genentech; Lilly; MapKure; Novartis; Pfizer; PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics

Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Eisai (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Ribon Therapeutics (Inst); Scorpion Therapeutics; Syros Pharmaceuticals (Inst); Takeda (Inst); Takeda (Inst)

Manish R.  Patel

Leadership - ION Pharma

Honoraria - Janssen Oncology

Consulting or Advisory Role - Accutar Biotech; Daiichi Sankyo/UCB Japan; Kura Oncology; Olema Pharmaceuticals

Research Funding - Accutar Biotech (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Artios (Inst); Artios (Inst); Artios (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BioNTech (Inst); BioTheryX (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Compugen (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Georgiamune (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hotspot Therapeutics (Inst); Hutchison MediPharma (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Incyte (Inst); Janssen (Inst); Kineta (Inst); Klus Pharma (Inst); Kura Oncology (Inst); Kymab (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); MabSpace Biosciences (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Nurix (Inst); nurix (Inst); Olema Oncology (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pionyr (Inst); Prelude Therapeutics (Inst); Puretech (Inst); PureTech (Inst); PureTech (Inst); Ribon Therapeutics (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Syndax (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); TeneoBio (Inst); Tesaro (Inst); Treadwell Therapeutics (Inst); Treadwell Therapeutics (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)

Linda R.  Duska

Consulting or Advisory Role - Ellipses Pharma; Inovio Pharmaceuticals; Merck; Regeneron

Research Funding - AbbVie; Advaxis; Aeterna Zentaris; Bristol-Myers Squibb; Cerulean Pharma, Aduro Biotech; Genentech/Roche; GlaxoSmithKline; Leap Therapeutics; Ludwig Institute for Cancer Research; Merck; Millennium; Morab; Morphotek; Novartis; Pfizer; Syndax; Tesaro

Patents, Royalties, Other Intellectual Property - Editor (for British Journal of Obstetrics and Gynaecology); UpToDate

Komal L.  Jhaveri

Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology

Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Clovis Oncology (Inst); Context Therapeutics (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical

Brian S.  Henick

Honoraria - DAVA Oncology; OncLive/MJH Life Sciences

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; IDEAYA Biosciences; Jazz Pharmaceuticals; Regeneron; Sorrento Therapeutics

Research Funding - Genentech/Roche (Inst); Johnson & Johnson/Janssen (Inst); NexImmune (Inst); Stand Up 2 Cancer (Inst); V Foundation (Inst)

Ursula A.  Matulonis

Honoraria - Alkermes; Symphogen

Consulting or Advisory Role - Agenus; Allarity Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Curelab Oncology; Eisai; GlaxoSmithKline; GlaxoSmithKline; Immunogen; Lilly; Merck; NextCure; ProfoundBio; Tango Therapeutics

Speakers' Bureau - Med Learning Group

Research Funding - Fujifilm; Immunogen; Leap Therapeutics; Merck; Mersana; Novartis; SQZ Biotech; Syndax; Tesaro

Travel, Accommodations, Expenses - AstraZeneca; Immunogen

Pamela N.  Munster

Leadership - Alessa Therapeutics

Stock and Other Ownership Interests  - Alessa Therapeutics; AtlasMedx; Hap10; OnKure; Parthenon Therapeutics; RasCal

Honoraria - JNJ; Olema Pharmaceuticals; Parthenon Therapeutics

Consulting or Advisory Role - Alessa Therapeutics; AtlasMedx; Olema Pharmaceuticals; RasCal

Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arch Oncology (Inst); Arvinas (Inst); Arvinas (Inst); Bliss Biopharmaceutical (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Cyteir; Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); IgM Biosciences (Inst); Immune Design (Inst); InventisBio (Inst); Merck (Inst); Novartis (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Seagen (Inst); Skorpion (Inst); Tempest Therapeutics (Inst); Xencor (Inst); Xynomic Pharma (Inst)

Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents

Other Relationship - ABIM Subspecialty Board; NIH/NCI

Michael J.  Birrer

Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Merck

Kathleen N.  Moore

Leadership - GOG Partners; NRG Oncology (Inst)

Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice

Consulting or Advisory Role - AADi; aadi; Alkermes (Inst); AstraZeneca; Blueprint Medicines (Inst); Caris Life Sciences; Clovis Oncology; Duality Biologics (Inst); Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); Hengrui Pharmaceutical; Immunogen; Iovance Biotherapeutics; Janssen Oncology; Merck; Mereo BioPharma; Mersana (Inst); Myriad Genetics; Novartis; Novartis/Pfizer; Onconova Therapeutics; OncXerna Therapeutics; Regeneron; VBL Therapeutics; Verastem/Pharmacyclics; zentalis

Research Funding - Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)

Patents, Royalties, Other Intellectual Property - UpToDate

Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline

Other Relationship - GOG Partners (Inst)

Giuseppe  Curigliano

Leadership - ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=

Honoraria - Ellipses Pharma

Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte

Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen

Research Funding - Merck (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech

Chia-Cheng  Li

Employment - Blueprint Medicines

Stock and Other Ownership Interests  - Blueprint Medicines

Jian  Guo

Employment - Blueprint Medicines

Stock and Other Ownership Interests  - Blueprint Medicines

Kevin  He

Employment - Blueprint Medicines

Stock and Other Ownership Interests  - Blueprint Medicines

Rentian  Wu

Employment - Blueprint Medicines

Stock and Other Ownership Interests  - Blueprint Medicines

Patents, Royalties, Other Intellectual Property - Blueprint Medicines

Sam  Tamulevich

Employment - Blueprint Medicines

Mikael  Rinne

Employment - Blueprint Medicines; Novartis Institutes for BioMedical Research

Stock and Other Ownership Interests  - Blueprint Medicines

Consulting or Advisory Role - Qiagen

Timothy A.  Yap

Employment - MD Anderson Cancer Center

Stock and Other Ownership Interests  - Seagen

Consulting or Advisory Role - 858 Therapeutics; Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amphista Therapeutics; Artios; Astex Pharmaceuticals; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avenzo; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; BioCity Pharma; Blueprint Medicines; Boxer; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Carrick Therapeutics; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Daiichi Sankyo; Dark Blue Therapeutics; Diffusion Pharmaceuticals; Duke Street Bio; EcoR1 Capital; Ellipses Pharma; EMD Serono; Entos; F-Star; Genesis Therapeutics; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; IDEAYA Biosciences; Idience; Ignyta; ImmuneSensor Therapeutics; IMPAC Medical Systems; Intellisphere; Janssen; Kyn therapeutics; MEI Pharma; Merck; Mereo BioPharma; Merit, Inc.; Monte Rosa Therapeutics; Natera; Nested Therapeutics; Nexys Therapeutics; Nimbus Therapeutics; Novocure; Odyssey Therapeutics; OncoSec; Ono Pharmaceutical; Onxeo; Oregon Health & Science University (OHSU); PanAngium Therapeutics; Pegascy; PER; Pfizer; Piper Sandler; Pliant; ProLynx; Radiopharma Theranostics; Repare Therapeutics; resTORbio; Roche; Ryvu Therapeutics; SAKK; Sanofi; Schrodinger; SERVIER; Synnovation; Synthis Therapeutics; Tango Therapeutics; TCG Crossover; TD2; Terns Pharmaceuticals; Terremoto Biosciences; Tessellate Bio; Theragnostics; Thryv Therapeutics; Tolremo; Tome; Trevarx Biomedical; Varian Medical Systems; Veeva; Versant Health; Vibliome Therapeutics; Voronoi Health Analytics; Xinthera; Zai Lab; ZielBio

Research Funding - Acrivon Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Boundless Bio; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); EMD Serono (Inst); F-Star (Inst); Forbius (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); IDEAYA Biosciences; ImmuneSensor Therapeutics (Inst); InSilico Medicine; Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Tango Therapeutics; Tesaro (Inst); Vivace Therapeutics (Inst); Zenith Epigenetics (Inst)